Pomerantz Law Firm Issues Reminder for Neumora Therapeutics Investors Amid Class Action Lawsuit and Key Dates

Investor Alert: Class Action Against Neumora Therapeutics

In an alarming turn of events, Pomerantz LLP has announced a class action lawsuit filed against Neumora Therapeutics, Inc. (NASDAQ: NMRA). This development has significant implications for investors who may have suffered losses due to their investments in Neumora. The class action centers around allegations of securities fraud and other unlawful business practices reportedly endorsed by the company and certain key officials.

About Neumora Therapeutics

Neumora is a biotech company that, as of September 15, 2023, conducted its initial public offering (IPO), successfully selling 14.71 million shares at a price of $17.00 each. However, what followed was a shocking revelation on January 2, 2025, when the company released data from the KOASTAL-1 study regarding their medication Navacaprant, designed to tackle moderate to severe major depressive disorder. The results indicated that the medication failed to show a statistically significant improvement on the critical endpoints specified for the study.

The Executive Vice President of Neumora, Rob Lenz, expressed disappointment over the findings, noting inconsistencies with prior supportive evidence for the treatment mechanism. The results influenced Neumora's stock value significantly, which plummeted by 81.42% to close at $1.97 per share on the very day the news was released.

Important Deadlines and Contacts

Investors who have incurred losses during this challenging period are strongly encouraged to take action promptly. They have until April 7, 2025, to request appointment as Lead Plaintiff in this class action. Such investors are advised to reach out to Danielle Peyton at the Pomerantz law firm via email at [email protected] or via their toll-free line, 888.4-POMLAW, extension 7980. For those interested, it's essential to provide a mailing address, phone number, and details of the shares purchased in the correspondence.

Pomerantz LLP: A Renowned Advocate

Founded by Abraham L. Pomerantz, who is sometimes referred to as the dean of the class action bar, Pomerantz LLP has spent over 85 years firmly establishing itself in the realms of corporate and securities class litigation. The firm has consistently fought for the rights of victims affected by fraudulent practices, breaches of fiduciary duty, and corporate misconduct, and has recovered millions of dollars for its clients over the years. With offices in major cities internationally, including New York, Chicago, and London, they remain a trusted name advocating for class members seeking redress through legal channels. Details regarding joining the class action can be found on their official website, www.pomerantzlaw.com.

As this legal situation unfolds, investors remain advised to stay informed and act quickly, given the pressing dates and potential for recovery from this tumultuous episode in the life of Neumora Therapeutics.

Final Notes

This notification serves as both an alert and an invitation for proactive measures to be taken by affected investors. With pressing deadlines looming, ensuring that one's voice is heard in court could potentially influence the outcomes of this lawsuit. Those interested in learning more about their rights, and the class action proceedings, should not hesitate to reach out to the Pomerantz Law Firm.